Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 70

Sort by

Sort Order Select

Journal Articles

A Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia

Nitin Jain, MD, Michael J. Keating, MD, Jan A. Burger, MD, PhD, Alessandra Ferrajoli, MD, Gautam Borthakur, MD, Charles Koller, MD, Srdan Verstovsek, MD, PhD, Susan O'Brien, MD, William G. Wierda, MD, PhD

Blood (2013) 122 (21): 4186.

https://doi.org/10.1182/blood.V122.21.4186.4186

Published: 2013

Journal Articles

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Alfonso Quintás-Cardama, M.D., Hagop M. Kantarjian, MD, Susan O'Brien, M.D., Elias J. Jabbour, MD, Guillermo Garcia-Manero, MD, Charles Koller, MD, Sherry A. Pierce, RN, BS, Moshe Talpaz, MD, Jorge E. Cortes, MD

Blood (2012) 120 (21): 918.

https://doi.org/10.1182/blood.V120.21.918.918

Published: 2012

Journal Articles

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Aziz Nazha, Carlos E. Bueso-Ramos, MD, PhD, Stefan Faderl, MD, Elihu H. Estey, MD, Susan M. O'Brien, Michael Farnandez, Martin Nguyen, Charles Koller, MD, Emil Freireich, MD, Miloslav Beran, Sherry Pierce, Jorge E. Cortes, MD, Hagop M. Kantarjian, MD, Farhad Ravandi, MD

Blood (2012) 120 (21): 2616.

https://doi.org/10.1182/blood.V120.21.2616.2616

Published: 2012

Journal Articles

Outcome of Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy

Hun Ju Lee, MD, Susan O'Brien, MD, Hagop M. Kantarjian, Farhad Ravandi, MD, Stefan Faderl, MD, Charles Koller, MD, Marina Konopleva, M.D., Ph.D., Srdan Verstovsek, MD, PhD, Tapan Kadia, Guillermo Garcia-Manero, Gautam Borthakur, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Deborah A. Thomas, MD, Jorge E. Cortes

Blood (2011) 118 (21): 1518.

https://doi.org/10.1182/blood.V118.21.1518.1518

Published: 2011

Journal Articles

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Hun Ju Lee, MD, Hagop M. Kantarjian, Deborah A. Thomas, MD, Stefan Faderl, MD, Charles Koller, MD, Alessandra Ferrajoli, MD, Elias Jabbour, Rebecca Garris, BSc, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, William G. Wierda, MD, PhD, Jan A. Burger, MD, PhD, Jorge E. Cortes, Susan O'Brien, MD, Farhad Ravandi, MD

Blood (2011) 118 (21): 1512.

https://doi.org/10.1182/blood.V118.21.1512.1512

Published: 2011

Journal Articles

Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)

Theresa Liu-Dumlao, MD, Susan O'Brien, MD, Jorge E. Cortes, Deborah A. Thomas, MD, Stefan Faderl, MD, Elias Jabbour, Charles Koller, MD, Rebecca Garris, BSc, Partow Kebriaei, MD, Richard Champlin, MD, Gautam Borthakur, Alessandra Ferrajoli, MD, Hagop M. Kantarjian, Farhad Ravandi, MD

Blood (2011) 118 (21): 2578.

https://doi.org/10.1182/blood.V118.21.2578.2578

Published: 2011

Journal Articles

Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI) Who Have a History of Prior Malignancies,

Paul B Koller, Hagop M Kantarjian, Charles Koller, Elias Jabbour, Susan O'Brien, Srdan Verstovsek, Gautam Borthakur, Zeev Estrov, Alfonso Quintas-Cardama, Jorge E Cortes

Blood (2011) 118 (21): 3787.

https://doi.org/10.1182/blood.V118.21.3787.3787

Published: 2011

Journal Articles

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Farhad Ravandi, Susan O'Brien, Jeffrey Jorgensen, Sherry Pierce, Stefan Faderl, Alessandra Ferrajoli, Charles Koller, Pramoda Challagundla, Sergernne York, Mark Brandt, Rajyalakshmi Luthra, Jan Burger, Deborah Thomas, Michael Keating, Hagop Kantarjian

Blood (2011) 118 (14): 3818–3823.

https://doi.org/10.1182/blood-2011-04-351502

Published: 2011

Journal Articles

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian, William G. Wierda

Blood (2011) 118 (8): 2085–2093.

https://doi.org/10.1182/blood-2011-03-341032

Published: 2011

Includes: Supplemental data

Journal Articles

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Sameer A. Parikh, Michael J. Keating, Susan O'Brien, Xuemei Wang, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Zeev Estrov, Xavier Badoux, Susan Lerner, William G. Wierda

Blood (2011) 118 (8): 2062–2068.

https://doi.org/10.1182/blood-2011-01-329177

Published: 2011

Journal Articles

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Xavier C. Badoux, Michael J. Keating, Xuemei Wang, Susan M. O'Brien, Alessandra Ferrajoli, Stefan Faderl, Jan Burger, Charles Koller, Susan Lerner, Hagop Kantarjian, William G. Wierda

Blood (2011) 117 (11): 3016–3024.

https://doi.org/10.1182/blood-2010-08-304683

Published: 2011

Includes: Supplemental data

Journal Articles

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

Jorge Cortes, Gautam Borthakur, Susan O'Brien, M.D., Dan Jones, Elias Jabbour, Farhad Ravandi, MD, Charles Koller, Brenda Walker, Jenny Shan, Hagop Kantarjian

Blood (2009) 114 (22): 338.

https://doi.org/10.1182/blood.V114.22.338.338

Published: 2009

Journal Articles

Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia.

Tapan Kadia, MD, Steven M. Kornblau, MD, Hagop Kantarjian, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Guillermo Garcia-Manero, MD, Gautam Borthakur, Charles Koller, MD, Srdan Verstovsek, MD, PhD, Sherry Pierce, RN, Jorge Cortes, MD, Farhad Ravandi, MD

Blood (2009) 114 (22): 330.

https://doi.org/10.1182/blood.V114.22.330.330

Published: 2009

Journal Articles

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Xavier C. Badoux, MBBS, Michael Keating, MD, Susan O'Brien, MD, Tapan Kadia, MD, Alessandra Ferrajoli, MD., Stefan Faderl, MD, Charles Koller, MD, Guillermo Garcia-Manero, MD, Jan A. Burger, MD, PhD, William G. Wierda, M.D., Ph.D,

Blood (2009) 114 (22): 3431.

https://doi.org/10.1182/blood.V114.22.3431.3431

Published: 2009

Journal Articles

Combination Therapy with Tyrosine Kinase Inhibitors and Agents with Different Mechnisms of Actions Is Effective in a Patient with Chronic Myeloid Leukemia Harboring the T315l BCR - ABL1 Mutation.

Fabio P S Santos, MD, Jorge Cortes, MD, Charles Koller, MD, Elias Jabbour, MD

Blood (2009) 114 (22): 4282.

https://doi.org/10.1182/blood.V114.22.4282.4282

Published: 2009

Journal Articles

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

Fabio P.S. Santos, MD, Susan O'Brien, MD, Deborah A. Thomas, MD, Jorge Cortes, MD, Stefan Faderl, MD, Jeffrey L. Jorgensen, MD, PhD, Rebecca Garris, Charles Koller, MD, Partow Kebriaei, MD, Alessandra Ferrajoli, MD, Hagop Kantarjian, MD, Farhad Ravandi, MD

Blood (2009) 114 (22): 984.

https://doi.org/10.1182/blood.V114.22.984.984

Published: 2009

Journal Articles

Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).

Blood (2009) 114 (22): 836.

https://doi.org/10.1182/blood.V114.22.836.836

Published: 2009

Journal Articles

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Sameer A Parikh, MD, Michael Keating, MD, Susan O'Brien, Alessandra Ferrajoli, Stefan Faderl, MD, Charles Koller, MD, Zeev Estrov, Susan Lerner, M.S., RHIA, William G. Wierda, M.D., Ph.D

Blood (2009) 114 (22): 208.

https://doi.org/10.1182/blood.V114.22.208.208

Published: 2009

Journal Articles

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Farhad Ravandi, MD, Hagop M. Kantarjian, MD, Jorge Cortes, MD, Deborah A. Thomas, MD, Stefan Faderl, MD, Dan Jones, MD, PhD, Elias Jabbour, MD, Charles Koller, MD, Samuel Dara, Rebecca Garris, Partow Kebriaei, MD, Gautam Borthakur, MD, Alessandra Ferrajoli, MD., Susan O'Brien

Blood (2009) 114 (22): 2043.

https://doi.org/10.1182/blood.V114.22.2043.2043

Published: 2009

Journal Articles

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Elias Jabbour, Daniel Jones, Hagop M. Kantarjian, Susan O'Brien, Constantine Tam, Charles Koller, Jan A. Burger, Gautam Borthakur, William G. Wierda, Jorge Cortes

Blood (2009) 114 (10): 2037–2043.

https://doi.org/10.1182/blood-2009-01-197715

Published: 2009

NARROW

A Phase II Trial Of Eltrombopag For Patients With Chronic Lymphocytic Leukemia (CLL) and Thrombocytopenia

Natural History and Potential for Cure of Patients with Chronic Myeloid Leukemia in Chronic Phase Receiving Frontline Therapy with Recombinant Interferon-Alfa: 30-Year Update From M.D. Anderson Cancer Center

Addition of All-Trans Retinoic Acid (ATRA) to the Combination of Fludarabine, Cytarabine, Idarubicin, with or without GCSF in Older, Higher Risk Patients with AML and High-Risk MDS Does Not Improve the Outcome in Those with NPM1 Mutation.

Outcome of Patients with Philadelphia Chromosome-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL) with Relapse After Tyrosine Kinase Inhibitor (TKI) Therapy

Long-Term Follow-up of Combined Hypercvad (hCVAD) Regimen with Dasatinib (Db) in the Front Line Therapy of Patients (pts) with Philadelphia Chromosome Positive (Ph+) Acute Lymphoblastic Leukemia (ALL)

Combination of the Hypercvad Regimen with Dasatinib in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) or Lymphoid Blast Phase of Chronic Myeloid Leukemia (CML-LB)

Outcome of Patients (pts) with Chronic Myeloid Leukemia (CML) Treated with Tyrosine Kinase Inhibitors (TKI) Who Have a History of Prior Malignancies,

Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia

Cyclophosphamide, fludarabine, alemtuzumab, and rituximab as salvage therapy for heavily pretreated patients with chronic lymphocytic leukemia

Frontline chemoimmunotherapy with fludarabine, cyclophosphamide, alemtuzumab, and rituximab for high-risk chronic lymphocytic leukemia

Fludarabine, cyclophosphamide, and rituximab chemoimmunotherapy is highly effective treatment for relapsed patients with CLL

Efficacy of Dasatinib in Patients (pts) with Previously Untreated Chronic Myelogenous Leukemia (CML) in Early Chronic Phase (CML-CP).

Clinical Characterization and Proteomic Consequences of Mutated Ras in Acute Myeloid Leukemia.

Chemoimmunotherapy with Cyclophosphomide, Fludarabine, Alemtuzumab and Rituximab (CFAR) Is Effective in Relapsed Patients with Chronic Lymphocytic Leukemia (CLL).

Combination Therapy with Tyrosine Kinase Inhibitors and Agents with Different Mechnisms of Actions Is Effective in a Patient with Chronic Myeloid Leukemia Harboring the T315l BCR - ABL1 Mutation.

Prognostic Impact of CD20 and CD25 Expression in Patients with Philadelphia-Positive (Ph + ) Acute Lymphoblastic Leukemia (ALL).

Chemoimmunotherapy with a Modified Hyper-CVAD and Rituximab Regimen Improves Outcome for Patients with De Novo Philadelphia Negative Precursor B-Cell Acute Lymphoblastic Leukemia (ALL).

Frontline Combined Chemoimmunotherapy with Fludarabine, Cyclophosphamide, Alemtuzumab and Rituximab (CFAR) in High-Risk Chronic Lymphocytic Leukemia.

Combination of the Hypercvad Regimen with Dasatinib Is Effective in Patients with Relapsed Philadelphia Chromosome (Ph) Positive Acute Lymphoblastic Leukemia (ALL) and Lymphoid Blast Phase Chronic Myeloid Leukemia (CML-LB).

Long-term outcome of patients with chronic myeloid leukemia treated with second-generation tyrosine kinase inhibitors after imatinib failure is predicted by the in vitro sensitivity of BCR-ABL kinase domain mutations

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only